COSENTYX (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the COSENTYX drug offered from Novartis Pharmaceuticals Corporation. This Interleukin-17A Antagonist [EPC],Interleukin-17A Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | secukinumab |
| SUBSTANCE NAME: | SECUKINUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Interleukin-17A Antagonist [EPC],Interleukin-17A Antagonists [MoA] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2015-01-21 |
| END MARKETING DATE: | 0000-00-00 |
COSENTYX HUMAN PRESCRIPTION DRUG Details:
| Item Description | COSENTYX from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 150(mg/mL) |
| START MARKETING DATE: | 2015-01-21 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0639_ccf89549-6649-4a7a-aa77-bb7644a69ea6 |
| PRODUCT NDC: | 0078-0639 |
| APPLICATION NUMBER: | BLA125504 |
Other SECUKINUMAB Pharmaceutical Manufacturers / Labelers:
